

PERSONAL INFORMATION



Sex | Date of birth | Nationality

WORK EXPERIENCE

01/08/2022 – Present

Biomedical Researcher – Coordinator of Clinical Trials

Unit of Haematology - Department of Specialised Medicine - Azienda Ospedaliero-Universitaria S. Anna - Via Aldo Moro, 8 – 44124, Ferrara (Italy). Involvement in clinical research and coordination and data managing of international/national/local clinical trials.

Principal Coordinator of International/National clinical research protocols:

- 1. DREAMM 14** (EudraCT 2021-004151-16, GSK, UK, original protocol date: 14-Sep-2021); *A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14).*
- 2. LOXO-BTK-20022** (EudraCT 2021-000043-49, Loxo Oncology, Inc. 09-Apr-2021) *A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)*
- 3. SYROS-MDS-1** (EudraCT 2020-004528-40, Syros Pharmaceuticals, Inc. 06 January 2021); *A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome.*
- 4. GIMEMA AML 2521** (EudraCT 2021-002361-17, CT.gov identifier NCT04867928); *A Multicentric Phase 2 Study of Venetoclax and Azacitidine for the management of molecular relapse/progression in adult NPM1-Mutated Acute Myeloid Leukemia.*
- 6. GIMEMA 2121** (CT.gov identifier NCT04867915); *Observational study on the diagnosis and management of chronic lymphocytic leukemia (CLL) in Italy by Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA).*
- 7. GIMEMA 2020** (CT.gov identifier NCT04640909); *Impact of treatment with targeted therapies on the generation of effective CAR T cells in patients with chronic lymphocytic leukemia.*
- 8. GIMEMA 1920** (CT.gov identifier NCT04282811); *An observational study to evaluate the clinical and biologic features and outcome of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens outside clinical trials in Italy.*
- 9. GIMEMA MDS0519 - ACROBAT trial** (EudraCT 2019-003997-25); *Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemotherapy, according to the BM-blast proportion.*
- 10. ROSCAPLI A Retrospective, Observational Study on the response to Caplacizumab treatment in aTTP patients: the Italian experience.** Fondazione Policlinico Universitario Agostino Gemelli – IRCCS – Università Cattolica del Sacro Cuore - Rome
- 12. REAL BELAMAF Studio Osservazionale su pazienti con Mieloma Multiplo Recidivato/Refrattario trattati con Belantamab Mafodotin in monoterapia precedentemente esposti ad almeno un inibitore del proteasome, un agente immunomodulatore e un anticorpo anti-CD38 (Observational Study in Patients with Multiple Recurrent Myeloma/Refractory Treated with Belantamab Mafodotin in monotherapy previously exposed to at least one proteasome inhibitor, one immunomodulating agent and one anti-CD38 antibody) - Fondazione EMN Italy ONLUS.**

Back-up Coordinator of International/National clinical research protocols:

- 1. GIMEMA AML 1819** (EudraCT 2019-003871-20, GIMEMA Foundation, Rome, original protocol date: 18-Nov-2019); *Phase III study to assess the impact of gemtuzumab ozogamicin, in combination*

with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as a posttransplant maintenance, in adult patients, aged 18-60 years, with previously untreated, de novo, favorable-intermediate-risk acute myeloid leukemia.

- 2. GIMEMA AML 1919** (EudraCT 2019-003936-21, GIMEMA Foundation, Rome, original protocol date: 11-Nov-2019); A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study. AMELIORATE (AML Early IntensificatiOn based on peRipheral bIAsT clearance).
- 3. GIMEMA-EORTC 1621-QLG-LG** (GIMEMA Foundation, Rome, original protocol date: 25-Jun-2018); A Survivorship Project to understAnd and to impRove long-Term outcomesfor Acute myeloid leukemia patients(SPARTA): The SPARTA platform.
- 4. GIMEMA QoL-APL0816** (GIMEMA Foundation, Rome, original protocol date: 27-Jul-2016); Long Term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated with Arsenic Trioxide (ATO) or Standard Chemotherapy).
- 5. GIMEMA CLL1114** (EudraCT 2014-002714-23, GIMEMA Foundation, Rome, original protocol date: 23-Oct-2014); A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL).
- 6. GIMEMA QoL-MDS 0108** (GIMEMA Foundation, Rome, original protocol date: 15-May-2008); Prognostic significance and longitudinal assessment of Patient-Reported Outcomes in Myelodysplastic Syndromes (PROMYS): PROMYS International Registry.
- 7. ARGX-113-2004** (EudraCT 2020-004032-21, argenx BV); A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia.
- 8. ARGX-113-2005** (EudraCT 2020-004032-21, argenx BV); A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia.
- 9. CLL17** (EudraCT 2019-003854-99, University of Cologne); A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL).
- 10. GERON-MYF3001-IMPactMF** (EudraCT 2020-003288-24, Geron Corporation); A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor.
- 11. MANIFEST-2** (EudraCT 2020-001989-10; Constellation Pharmaceuticals, Inc.); A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
- 12. GIMEMA CLL1618** (Clinicaltrial number NCT03528941, GIMEMA Foundation, Rome, original protocol date: 24-Apr-2018); Observational retrospective multicenter Study aimed at evaluating the incidence of Hepatitis B reactivation in patients affected by Chronic Lymphocytic Leukemia treated with Ibrutinib.
- 13. GIMEMA-CLL1518** (EudraCT 2018-000877-61, GIMEMA Foundation, Rome, original protocol date: 05-Feb-2019); Activity and safety of front-line venetoclax and rituximab association (VeRiTAs) in young and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or disrupted TP53. A phase 2 multicenter study.
- 23. GIMEMA-CLL1818** (EudraCT 2019-000159-14, GIMEMA Foundation, Rome, original protocol date: 04-Sep-2019); Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemotherapy and Tenofovir Alafenamide.
- 24. GIMEMA-LLC1215** (EudraCT 2015-000684-13, GIMEMA Foundation, Rome, original protocol date: 30-Sep-2015); A Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogeneic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia.
- 25. GIMEMA-CML1415 - SUSTRENIM Study** (EudraCT 2015-005248-33, GIMEMA Foundation, Rome); Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response.
- 26. GIMEMA-EORTC 1621-QLG-LG** (GIMEMA Foundation, Rome, original protocol date: 25-06-2018); A Survivorship Project to understAnd and to impRove long-Term outcomesfor Acute myeloid leukemia patients (SPARTA): The SPARTA platform.

14/05/2012–30/06/2022

Biomedical Researcher – Principal Coordinator of Clinical Trials

Unit of Thalassaemia and Haemoglobinopathies (DHTE) – Hub Centre of the Regional

Hub&Spokes net - Department of Medicine - Azienda Ospedaliero-Universitaria S. Anna - Via Aldo

Moro, 8 – 44124, Ferrara (Italy).

International/National clinical research protocols

1. **ACE 536-06** (EudraCT 2014-001281-94, Acceleron Pharma, original protocol date: 14-Apr-2014); *An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients with β -Thalassemia Previously Enrolled in Study A536-04.*
2. **THALAMOSS THEME [HEALTH.2012.1.2-1]** [Development of technologies with a view to patient group stratification for personalised medicine applications] (Grant agreement for collaborative project no. 306201) *THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia.*
3. **e-MIOT**: Extension-Myocardial Iron Overload in Thalassemia; experimental multicentre no-profit study aimed at validating the MRI multislice multi-echo T2* sequences as a non-invasive technique for the monitoring of pancreatic iron overload in thalassaemia, sickle cell disease and thalasso-drepanocytosis CNR, Pisa, Italy.
5. **LicNet** (Liver Italian Cutino NETwork); prospective multicentre observational study (vs. 1.1, 11 Sep 2015; sponsor Associazione Piera Cutino Onlus Palermo, Italy) for the iron overload monitoring in thalassaemia patients with primary or secondary haemochromatosis, aimed at determining the more appropriate chelation therapy.
5. **ACE-536-B-THAL-001** (EudraCT no. 2015-003224-31; IND no. 112,562, Celgene Corporation, New Jersey, USA): "A phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ace-536) versus placebo in adults who require regular red blood cell transfusions due to beta-thalassemia".
6. **2012-101** (EudraCT 2012-000955-15 Novartis, Release Date: 13-Jul-2012) *A phase IIa open-label, single arm, multi-center trial evaluating the safety of standard antiviral therapy (pegylated interferon and ribavirin) plus deferasirox in thalassemia patients with transfusion dependent iron overload and chronic hepatitis C.*
7. **CICL670E2001I**, *Deferasirox treatment of iron overload in-patient with non-transfusion-dependent beta-thalassaemia intermedia* (Compassionate, Novartis).
8. **CICL670F2201** (EudraCT 2013-004167-32, Novartis, Release date: 28-Jan-2014) *A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet).*
9. **ACE 536-04** (EudraCT 2012-002499-15, Acceleron Pharma, original protocol date: 06-Aug-2012); *A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β -Thalassemia.*
10. **SPD602** (EudraCT 2011-005675-16, Shire Dev. LLC, USA, original protocol date: 12-Dec-2011); *A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two SSP-004184 (SPD602) Doses in the Treatment of Chronic Iron Overload Requiring Chelation Therapy.*
11. **CICL670AIT-14** (Observational, retrospective renal safety study – Novartis, release date: 09-Sep-2014); *A retrospective data collection study to assess the long-term renal safety of deferasirox in patients with transfusion hemosiderosis who were enrolled into the registration studies.*
12. **MIOT - Myocardial Iron Overload in Thalassaemia: Multicenter experimental study, controlled, open, phase III, sponsored, "no profit", to validate sequences of magnetic resonance images (MRI) cardiac multislice multi-echo T2* and hepatic T2* gradient-echo, a non-invasive monitoring of cardiac and hepatic iron overload in thalassaemia and sickle cell disease patients; CNR, Pisa, Italy.**
13. **Thal2015** (vs. 01.4, 24-Jul 2015 of the original vs. 11 Jan 2015); "A pilot multicenter open-label study on treatment with Sofosbuvir/Ledipasvir FDC (Harvoni) in patients with thalassaemia major and chronic HCV infection". A no-profit Italian multicentre study sponsored by Unit of Hepatology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
14. **CICL670AIC04** (EudraCT 2016-000186-23, Novartis, 12-Feb-2016) "Open-label, multicenter, single arm, phase III study to collect additional safety and efficacy data with deferasirox film coated tablets in patients completing study CICL670F2201".
15. **CICL670F2429** (EudraCT 2016-003482-25, Novartis, 12-Sep-2016), Development phase IV; "A single-arm interventional Phase IV, post-authorization study evaluating the safety of pediatric patients with transfusion hemosiderosis treated with deferasirox crushed film coated tablets".
16. **ACE-536-LTFU-001** (EudraCT no. 2018-002915-93; IND no. 112562, Celgene Corporation, New Jersey, USA). "A Phase 3B, Open-label, single-arm, rollover study to evaluate long-term safety in

subjects who have participated in other Luspatercept (ACE-536) clinical trials".

17. NPP-LUS-ITA-001. Compassionate protocol; CELGENE / Bristol Mayer Squibb Co. "Therapeutic program guidance document for the use of luspatercept in adult patients with transfusion-dependent anemia associated with beta-thalassemia"; vs. 1.5.).

18. AG348-C-018. "A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)"; Agios Pharmaceuticals, Inc., Cambridge, MA, USA. EudraCT 2021-000212-34; NCT04770779; IND Number 119825.

19. AG348-C-017. "A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)" Agios Pharmaceuticals, Inc., Cambridge, MA, USA. EudraCT 2021-000211-23; NCT04770753; IND Number 119825.

20. VIT-2763-THAL-203. (EudraCT 2021-001639-23; IND no. 147878, Vifor International Inc.). National Coordinator Centre. "A Phase 2b, double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent β -thalassaemia".

21. 2021_HEMOGLOB-VAX_COVID19. "Monitoraggio della vaccinazione anti-SARS-CoV-2 (COVID 19) e anticapsulati in una coorte di pazienti con Sindromi Talassemica e Falcemica - HEMOGLOB-VAX"; AIFA; Sponsor: Società Italiana Talassemie ed Emoglobinopatie (SITE, Italian Society Thalassaemia and Haemoglobinopathies); Coordinator Site: Dipartimento OncoEmatologia, Terapia Cellulare, Terapie Geniche e Trapianto Emopoietico Ospedale Pediatrico Bambino Gesù, IRCCS - Roma, Italy.

Local clinical protocols

- 1. Three Haemocomponents** (vs.00 20-Dec-2016). Observational, no-profit; "Impact Assessment of three different haemocomponents on transfusion indices in β -thalassaemia patients".
- 2. Two haemocomponents** (Vs.00 14-Jul-2017). Cross-over, no-profit, "Prospective, crossover study on multitransfused patients with β -Thalassaemia to assess the impact on transfusion regimen of two types of pre-storage leukodepleted erythrocyte packed units (in-line filtration and buffy-coat removal; whole-blood filtration with buffy-coat maintenance)".
- 3. Thal-Ther** (v.00 15-05-2018). "Studio dell'attività di biomolecole, utilizzate anche in combinazione, sui precursori eritroidi isolati da pazienti con β -Talassemia seguiti presso il Centro di Ferrara e valutazione del rapporto tra polimorfismi del DNA e risposta in termini di incremento dell'emoglobina fetale" (Investigating on biomolecules activity, also combined, on erythroid precursors purified from β -Thalassaemia patients cared at Healthcare Centre of Ferrara, and assessment of the relationship between DNA polymorphisms and outcome in terms of foetal haemoglobin increase). EC internal code: 533/2018/Sper/AOUFe.
- 4. Sirthalacilin** (EudraCT no. 2018-001942-33; MTA code CT2-02-17; Sponsor: Rare Partners srl, Milan, Italy; vs. 1.0 05-Nov-2018). "A personalised medicine approach for beta-thalassemia transfusion-dependent patients testing SIROLIMUS in a first pilot clinical trial". Interventional, pilot, single-center, open-label phase 2 study.
- 5. Pathipofthal** (V.00 10-Oct-2018; EC-code 69012018/Oss/AOUFe). Observational study. Ongoing.
- 6. Thala-Rap** (EudraCT no. 2018-001469-18; MTA code CT2-04-17; Sponsor: University of Ferrara – Department of Life Sciences and Biotechnologies). "Treatment of beta-thalassemia patients with rapamycin (sirolimus): from pre-clinical research to a clinical trial".

24/Apr/2015 – 30/Apr/2021

Research grant on the topic: "**Building a database of patients with beta-thalassemia for stratification based on clinical parameters**" (Original title: *Costruzione di un database di pazienti con beta-talassemia per una stratificazione basata su parametri clinici*) – Department of Life Sciences and Biotechnologies – University of Ferrara.

07/Sep/2015 - 31/Sep/2016: Professional work performance – University of Ferrara

14/May/2012 – 31/May/2014: Contract of continuous collaboration - Consorzio Ferrara Ricerche, University of Ferrara, Italy. Main tasks:

- Clinical data management on haemoglobinopathies and management of local HER

(database structuring, designing and building related procedures; documentation, evaluation and basic statistics of data merging and derived datasets).

- Coordination of HUB&Spokes Rare Anaemia Regional Site Network
- Teaching for professionals (occasional): Tropical Infectious Diseases; Conduction and Management of Clinical Trials.
- Scientific coordination of International/National/Local Clinical trials in accordance with study protocol requirements and in compliance with ICH – GCP guidelines.

14/03/2011–15/03/2016

Biomedical Research

Unit of Paediatric Haematology and Oncology – Department of Growth and Development - Azienda Ospedaliero-Universitaria S. Anna - Via Aldo Moro, 8 – 44124, Ferrara (Italy). Contract of continuous collaboration - Consorzio Ferrara Ricerche, University of Ferrara, Italy.

Data management and study coordination in accordance with protocol requirements and in compliance with ICH – GCP guidelines. Clinical trials:

- **EuroNet PHL-LP1** – *First international inter-group study for nodular lymphocyte-predominant Hodgkin's Lymphoma in children and adolescents* (EudraCT no. 2007-004092-19, Date of version: 29-Jun-2011; Martin Luther University of Halle/Wittenberg; Italian Coordinating Site: Unit of Paediatric Haematology and Oncology, Ferrara)
- **Inter-B-NHL Ritux 2010** - *Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of rituximab efficacy and safety in high-risk patients* (EudraCT no. 2010-019224-31; Date of version 1.1: 09-Sep-2011; Institute Gustave Roussy-114, rue Edouard Vaillant 94 805, Villejuif-France).

Occasional teaching: Biology and microenvironment of HL, AML, ALL (addressed to physicians specialising in Paediatrics).

04/02/2008–30/04/2010

Direction of Clinical Laboratory

University of Verona – Department of Life Sciences and Reproduction - Unit of Pediatrics, Policlinico G.B. Rossi, P.le Scuro, 4 – 37134 Verona (Italy) – Contract of continuous collaboration. Location: Hôpital Autonome de Ngozi, Ngozi – BP 6, Burundi.

- Responsible of Clinical Laboratory (Setting up and conduction; staffing and specific training laboratory personnel; introduction and application of GCP in district health care and SOPs application)
- Blood Bank Coordination (specific training of laboratory personnel; introduction and application of GCP)
- Training of clinical laboratory and hospital staff on clinical laboratory management and conduction in compliance with WHO general guidelines.

Sector Direction and Education

15/11/2007–15/04/2010

Teaching professional

University of Verona – Department of Life Sciences and Reproduction - Unit of Pediatrics, Policlinico G.B. Rossi, P.le Scuro, 4 – 37134 Verona (Italy) – Contract of continuous collaboration. Location: Institut Universitaire des Sciences de la Santé du Burundi - BP 137 Ngozi (Burundi)

- Lessons: Histology; Human Anatomy.
- Responsible for the examination committee.

- 12/08/2005–11/07/2007 **Direction of Clinical Laboratory and Consultant of Ministry of Foreign Affairs**
Emiliano De Marco, Italian ONLUS Association; IBO Italia NGO. Project collaboration contract.
Location: St. Orsola Catholic Hospital, Matiri Mission, Tharaka District, P.O. Box 41, 60200 Meru, Eastern Province (Kenya). Responsible of Clinical Laboratory and Blood Bank.
- Clinical Laboratory:** Setting up and conduction; staffing and training technologists, technicians, laboratory officers and assistants; introduction and application of GCP in district health care and SOPs application. Upgrading and career development. Coordination of regional hospital departments.
- TQM:** SOPs in pre-analytical, analytical, post-analytical phases and relevance, interpretation and clinical impact of analytical results, management and maintenance of equipment/instrument.
- Training:** General laboratory conduction; diagnostic tests ability; reference ranges in clinical practice and local reference ranges assessment; epidemiology of public clinical health.
- Mobile laboratory:** Regulations and practice; SOPs and staff PPE (personal protective equipment) application.
- Logistics:** Expenses estimation; management of storage and inventory register; selection of essay and resolution of fault in finance management.
- Health and safety programme:** Risk assessment (identification of risk group microorganisms); safety measures application; use and maintenance of biological safety cabinets; transporting specimen regulations (Safety in health-care laboratories – WHO) with PPE application.
- Hazards:** Classification, storage and use of flammable, oxidizing, toxic, harmful, irritating, corrosive, explosive chemicals, preventing accidents programme. Decontamination procedures, special waste recycling and disposal (in accordance with WHO procedures). Firefighting equipment and guidelines to reduce fire risk.
- Software basic:** Microsoft Office (Excel, Access, Word and PowerPoint).
- Blood transfusion service:** In collaboration with Regional Transfusion Centre, Embu - Kenya: International guidelines/SOPs in tropical countries; QA and management responsibilities; blood donations in critical situations; screening of regional donors; investigational procedures of transfusion reaction; statistical management and reports for the Regional Centre headquarter.
- Medical seminars:** organisation and conduction for professionals.
- Business or sector Professional, scientific and technical activities.

- 01/09/1997–31/01/2005 **Biomedical research**
Day Hospital Thalassaemia – Department of Paediatrics and Endocrinology and Unit of Blood Bank – Azienda Ospedaliero-Universitaria S. Anna , C.so della Giovecca, 203 - 44100 Ferrara (Italy).
- Day Hospital Thalassaemia**
Sep/1997-Jun/2001: Scholarship holder of Associazione per il Bambino Talassemico (grant by Apotex Industry-Canada)
26-Feb-2004: Intellectual work performance assignment (Novartis Farma, S.p.A., Italy; Protocol CICL670A0107)
01/Mar/2001 – 31/Mar/2005: Contract of continuous collaboration - Consorzio Ferrara Ricerche, University of Ferrara, Italy on the following topics: Clinical data management and creation of local databases and Standard Statistical Analysis on:
- *Survival analysis and causes of death* in β -Thalassaemia since 1956.
 - *Auxo-endocrinological studies* in collaboration with Giambrone Thalassaemia Association, Cagliari, Italy and Institut für Sozial und Präventivmedizin der Universität, Zürich, Switzerland.
 - *Evaluation study* on Liver iron compound (LIC) by SQUID in collaboration with Abt. Medizinische, Biochemie, Universitätskrankenhaus Eppendorf, Hamburg, Germany and Microcitemia Centre, Turin, Italy.
 - *Observational studies:* Endocrinopaties and cardiac disorders; ACTH tests and biometrical evaluation of bone age (TW₂₀) in paediatric patients; statistical evaluation of LIC by SQUID vs. LIC

by liver biopsy; effect of Interferon-Ribavirin treatment in chronic hepatitis HCV-correlated.

- Study on DNA spermatid cells damage in β -Thalassaemia, in collaboration with Departments of Obstetrics and Gynaecology and Haematology, UCL London - MCR Reproductive Biology Unit, Edinburgh, UK.
- *Comparative study on Deferrioxamine and Deferiprone chelating agents and bone metabolism in β -Thalassaemia Major* (Chiesi S.p.A.; Rizzoli Orthopedic Institut –IOR-, Bologna, Italy).

Scientific Coordination - Observational and interventional trials (phases II-III-IV):

- *"Safety and efficacy of red blood cells stored in 0.5 CPD/ Erythro-sol versus in CPD/SAG-M in transfusion-dependent thalassaemia patients"* (Fenwal R&D Group, Baxter Europe, Belgium) - S. Anna Hospital and Department of Biomedical Studies, University of Ferrara, Italy
- Pharmacokinetic and pharmacodynamics of oral chelating agent deferiprone (Phase II-III, Apotex S.p.A., Canada)
- Oral chelating treatment with ICL670 (Ferriprox) in thalassaemia patients (Novartis S.p.A.)
- Biometrical evaluation of deferiprone and deferoxamine chelating agents (Phase IV, Novartis, S.p.A.).

Blood Bank

- **1998-2000:** Occasional consultancy activities on the following topics: *"Checking of performance and safety of equipment and blood/plasma filtration systems"* and *"Bibliographic investigation and scientific reports priming pertaining to the above-mentioned activity"* (Biofil, Gruppo Fresenius S.r.L., Italy)
- **01/Oct/1997 – 30/Sep/1998:** Scholarship holder of Azienda Ospedaliero-Universitaria S. Anna (measure number 1029 of 23-Sep-1997) on the topic: **"Transport of oxygen in transfusion-dependent thalassaemia patients"** (Original title: *Trasporto di ossigeno in pazienti talassemici trasfusione-dipendenti*)

Business or sector Professional, scientific and technical activities.

03/1991–04/1994

Clinical Laboratory Biologist

Department of Nuclear Medicine (RIA Laboratory) – Clinic of Obstetrics and Gynecology
Azienda Ospedaliero-Universitaria S. Anna - Corso Giovecca 203, 44100 Ferrara (Italy).

- (Radio-Immune assays (Analyst): Thyroid, pituitary, steroid and ovarian hormones, pregnancy assessments.
- 01/May/1992 – 30/Nov/1992 Scholarship holder of Azienda Ospedaliero-Universitaria S. Anna (measure number 1193 of 30-Apr-1992) on the topic: **"Study of calciotropic hormones in different physiological and pathological situations"** (Original title: *Studio degli ormoni calciotropi in diverse situazioni fisiologiche e patologiche*)

Preliminary study: *Circadian Cycles - Hormones evaluation in a healthy population.*

Business or sector Professional, scientific and technical activities

EDUCATION AND TRAINING

02/1989–02/1990

Professional Biologist Doctor (National Board registration no. AA_034327)

EQF level 3

Clinical Laboratory - Azienda Ospedaliero-Universitaria S. Anna - 203, Corso della Giovecca, 44100 Ferrara (Italy).

- Clinical Laboratory: Post-graduate training: electrophoresis, haematology, clinical chemistry, microbiology, serology, flow cytometry.
- Professional qualification acquired Professional Biologist Doctor with enrolment in the professional register (Biologists National Board registration no. 034327).

15/10/1988

Degree in Life Sciences

EQF level 6

University of Ferrara, Ferrara (Italy). Clinical pathological address according with the old rule.

Experimental Thesis – Institute of General Pathology, University of Ferrara. Title: *Infectious diseases during pregnancy. Investigation on pregnant women of Ferrara District (Original title: Malattie infettive in corso di gravidanza. Indagine su un campione di gravide della Provincia di Ferrara)*.

Qualification acquired **Biologist Doctor in accordance with the old university system.**

27/07/1979

Diploma in Scientific studies

EQF level 1

Science High School (Scientific Lyceum A. Roiti, Ferrara, Italy).

PERSONAL SKILLS

Mother tongue(s) **Italian**

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
French	C2	C2	C2	C2	C2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and **C2: Proficient user**
Common European Framework of Reference for Languages

Communication skills Good communication skills gained through professional experiences. Excellent contact with students and professionals gained through teaching experience.

Organisational / managerial skills **Mar/Jun-2005: Language Cultural Centre "International Communication S.A.S.", Ferrara, Italy.** Secretariat, promotion of language courses, teachers activity assistance.

Digital skills

Information processing	SELF-ASSESSMENT			
	Communication	Content creation	Safety	Problem solving
Proficient user	Proficient user	Independent user	Proficient user	Proficient user

Good command of Office suite: **Microsoft Office package** (Access, Excel, Power Point, Word)

Good command of the following **Statistical Softwares**: Statgraphics (Manugistics), MedCalc, PSP.2K (Personal Statistic Package by Servizio Fisica Sanitaria-S.Anna Hospital, Ferrara, Italy)

Past: 1985-1988 IBM-XT computer in connection with CDC CYBER 180/860 A (disabled at the present) - C.I.N.E.C.A. (Inter-University Electronic Centre, North-eastern Italy) Casalecchio di Reno-Bologna using N.O.S. (Network Operating System) and SPSS-X (Statistical Package for Social Sciences for biometrical evaluations). DBF-III.

Good command of the following **Clinical laboratory instruments**: Haematology coulter, clinical chemistry and coagulation analysers, flow cytometer, PCR.

Driving licence A, B

ADDITIONAL INFORMATION

Trainings and Certifications

1. **"Medidata Rave eCOA Form Availability"** (*Rave EDC; Rave EDC (SIMT); Patient Cloud Registration; Patient Cloud; Rave Modules*); Certificate of completion - Medidata Academy – Aug 9, 2022.
2. **"Vault CDMS for Clinical Research Coordinators"; "Vault CDMS What's New in 22R2"**. Certificate of completion, awarded on (UTC) – Veeva Vault CDMS – Aug 8, 2022.
3. **"Advanced Rave EDC for Site Users"** Certificate of completion - Medidata Academy – Aug 8, 2022.
4. **"Classic Rave EDC Lab Data Handling"** - Certificate of completion - Medidata Academy – Aug 8, 2022.
5. **"Medidata Rave EDC: Creating a Subject"** (*Rave EDC; Rave EDC (SIMT); Patient Cloud Registration; eConsent Dashboard; Rave Modules; Rave EDC Labs*) Certificate of completion - Medidata Academy – Aug 8, 2022.
6. **"Medidata Rave eCOA: Overview; Site Mode; Registering Your Subject in an ePRO Study"; ClinRO (Rave EDC; Rave EDC (SIMT); Patient Cloud Registration; eConsent Dashboard; Rave Modules)"** - Certificate of completion - Medidata Academy – Aug 8, 2022.
7. **"Vault CDMS What's New in 22R2"** Certificate of completion, awarded on (UTC) – Veeva Vault CDMS – Aug 5, 2022.
8. **"Classification, Identification, packaging requirements, marking and labelling requirements, documentation requirements, emergency action requirements for shipment of cat. A (infectious substance affecting humans) and cat. B (biological substance)".** Record of Training – Mayo Clinic 49CFR 172.700/IATA 1.5_Jul 7, 2022. Score 100%
9. **"Transporting dangerous goods training"**. Certificate of attendance – Mayo Clinic Laboratories–ASCLS P.A.C.E. CA Accrediting Agency 0001 Provider # 058; CEU 1 – Jul 7, 2022
10. **"Introduction to Collecting and Reporting Adverse Events in Clinical research"** Certificate of Completion – The Global Health Network – e-learning course Apr 28, 2022. Score 100%.
11. **"The Research Question"** Certificate of Completion – The Global Health Network – e-learning course Apr 21, 2022. Score 100%.
12. **"Introduction to Informed Consent"** Certificate of Completion – The Global Health Network – e-learning course Apr 21, 2022. Score 100%.
13. **"Introduction to Data Management for Clinical Research Studies"** Certificate of Completion – The Global Health Network – e-learning course Apr 21, 2022. Score 100%.
14. **"The Study Protocol. Part two"** Certificate of Completion – The Global Health Network – e-learning course Apr 16, 2022. Score 100%.
15. **"Data safety and Monitoring Board for Clinical Trials"** Certificate of Completion – The Global Health Network – e-learning course Apr 16, 2022. Score 100%.
16. **"The Study Protocol. Part one"** Certificate of Completion – The Global Health Network – e-learning course Apr 15, 2022. Score 100%.
17. **"Introduction to clinical research"** Certificate of Completion – The Global Health Network – e-learning course Apr 12, 2022. Score 100%.
18. **"Medidata Rave EDC: Clinical Research Coordinators (Rave EDC, Rave EDC (SIMT), Patient Cloud Registration, Rave Modules and eConsent Dashboard)"** Certificate of Completion - Medidata Rave EDC: Clinical Research Coordinators, Medidata. Application – Mar 30, 2022
19. **"Corso AVEC - Tutela dei dati e sicurezza informatica per profili sanitari 2"** (Data protection and IT security for health issues. Edition 2). CE-AVEC, Bologna. Distance formation nr. 5009.2. Nov 23, 2021.
20. **"Prevenzione della corruzione e dell'illegalità nella pubblica amministrazione. Edizione 2"** (Prevention of corruption and illegality in public administration. Edition 2). CE-AVEC, Bologna. Distance formation nr. 4870.2. Nov 23, 2021.

21. **“Gestione del rischio clinico per il contenimento delle infezioni correlate all’assistenza (COVID-19)”** (Clinical risk management for containment of care-related infections (COVID-19). Nov 8, 2021. Objective: Special issues of the National and/or Regional Health Service of urgent nature; clinical risk system expertise for patient care professionals COVID-19; special topic: coronavirus infection 2019-nCoV. Meeting Service, Provider accreditation nr. 4961 - Provider ECM n. 312618, edition 1. 1 Dec 2019 - **CME points: 50.**
22. **“Nuovo codice deontologico dei biologi-III”** (New deontological code of ethics for biologists-III). Oct 31, 2021. Distance formation nr. 309990 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 6.**
23. **“Le interazioni farmaci-alimenti”** (Le interazioni farmaci-alimenti). Oct 30, 2021. Distance formation nr. 308733 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 6.**
24. **“La promozione della salute e la valutazione di impatto sanitaria (VIS): nuovi orizzonti professionali per il biologo”.** (Health promotion and health impact assessment (HIA): New professional horizons for biologists). Nov 6, 2021. Distance formation nr. 316057 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 4.5.**
25. **“Il Sistema integrato della sicurezza alimentare”** (The integrated food safety system). Nov 1, 2021. Distance formation nr. 313530 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 3.**
26. **ICH Good Clinical Practice E6 R2** – e-learning course Nov 18, 2020 - Global Health Training Centre. Score 100%.
27. **“La comunicazione in sanità”** – (Communication in healthcare) - Dec 5, 2019 - Distance formation nr. 267/248021 – O.P.E.S. association provider on the behalf of the National Commission for Continuous Vocational Training (CVT), accreditation nr. 267. **CME points: 10.**
28. **“Rischi specifici sui luoghi di lavoro”** – (Specific risks at the workplace) – Dec 5, 2019 - Distance formation nr. 267/247950 – O.P.E.S. association provider on the behalf of the National Commission for Continuous Vocational Training (CVT), accreditation nr. 267. **CME points: 50.**
29. **“Applicare il GDPR in ambito sanitario (EU 679-2016- Corso base 2019)”** – Meeting Service – sas - Provider ECM n. 4967. 1 Dec 2019 - **CME points: 30.**
30. **“Rischi per la salute, vaccinazione e profilassi: ruolo del professionista sanitario”** (Health risks, vaccination and prophylaxis: role of the health care professional). Nov 9, 2019. Distance formation nr. 267/247967 – O.P.E.S. association provider on the behalf of the National Commission for Continuous Vocational Training (CVT), accreditation nr. 267. **CME points: 20.**
31. **“Ruolo dei test di funzionalità piastrinica nella scelta della terapia antiaggregante per i pazienti con sindrome coronariche acute”** (Role of platelet function assessments in terms of choosing the antiplatelet therapy in patients with acute coronary syndromes). Nov 6, 2019. Distance formation nr. 278024 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 5.**
32. **“Il sopralluogo giudiziario”** (The judiciary inspection). Nov 2, 2019. Distance formation nr. 275302 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 5.**
33. **“Introduzione alla genetica forense”** (Introduction to forensic genetics). Nov 2, 2019. Distance formation nr. 2705844 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 5.**
34. **“Nuovi scenari diagnostici delle infezioni sessualmente trasmissibili”** (New diagnostic scenarios of sexually transmitted infections). Oct 30, 2019. Distance formation nr. 265570 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 3.**
35. **“Interazioni tra fitoterapici e farmaci convenzionali”** (Interactions between phytotherapics and conventional drugs). Oct 30, 2019. Distance formation nr. 262996 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 3.**
36. **“Effetti positivi di una dieta controllata sul tono dell’umore e sui parametri biochimici in pazienti con sindromi coronariche acute”** (Benefits of a controlled diet on patients with acute coronary syndromes). Oct 30, 2019. Distance formation nr. 267172 – National Board (ONB) provider, accreditation nr. 6179. **CME points: 3.**
37. **Medidata Rave EDC: Understanding Lab Forms; Task Management; Markings;**

Getting Started; About Log Forms; Entering and Editing Data. Medidata Cloud Administration Navigation Bar. Application: Rave EDC, Rave EDC (SIMT), Patient Cloud Registration, and Rave Modules. Medidata University, Oct 7, 2019.

38. **OC-RDC 5.2 delta training**, Novartis-GBS (IQVIA™), Nov 16, 2018.
39. **Good Clinical Practice (GCP) ICH E6 R2 training**, Oct 22, 2018, Celgene Corporation, 86 Morris Avenue - Summit, NJ 07901.
40. **GCP Compliance Training for HCPs V2.0** (based on ICH E6 (R2) GCP Guidelines; Jan 31, 2018, on the behalf of Novartis.
41. **RDC Onsite_version 5.0.1 training**, Jan 25, 2018, on the behalf of Novartis.
42. **"Sicurezza negli ambienti e nei luoghi di lavoro e/o patologie correlate"** (Safety in working environments and workplaces and/or related diseases) – Continuing Education in Medicine – Nov 11-24, 2016. Provider Azienda USL of Ferrara and Azienda Ospedaliero-Universitaria of Ferrara. Code: CO1600587-1. **CME points: 18.**
43. **OC-RDC training, Novartis-GBS (IQVIA™)** - Aug 22, 2016.
44. **Oracle RDC 4.5.3/4.6 - Quintiles training** - Aug 8, 2016.
45. **Rave EDC completion**– Medidata Academy – Jun 3, 2016.
46. **ICH Good Clinical Practice** – E-learning course Apr 21, 2016 – Global Health Training Centre – Certificate no. 115178 (Score 100%).
47. **GCP e-learning training – Novartis** – Azienda Ospedaliero-Universitaria S. Anna di Ferrara. Dec 17, 2014.
48. **ERT SITEpro Training – Protocol ACE536-04** – Acceleron Pharma, Inc. Apr 7, 2014.
49. **"Rave EDC Essentials for Clinical Research Coordinators"** Certified Professional - Clinical Research Coordinator ID# MDSO3224880 - Medidata University, Sep 11, 2013.
50. **GCP Training** – Investigator meeting and participation in clinical trial *"Intergroup Trial for children and adolescents with B-cell NHL or B-AL: evaluation of Rituximab efficacy and Safety in High risk patients"*. Unit of Hematology and Oncology - A.O.U. S. Anna, Ferrara. May 24, 2013.
51. **"Protocol and GCP Training - Protocol 2012-101"**. Novartis, Jan 17, 2013.
52. **"Opis ICH-GCP and Project specific eCRF Training for Data Management - Protocol 2012-101"**. Novartis. Jan 17, 2013.
53. **"ICH-GCP Site training Log – Data Manager and Study Coordinator - Training slides version 1_Final_07-Sept-2012"**, Chiltem International srl – Milan (Italy); Clinical Trial ACE 536-04. Dec 11, 2012.

Conferences

1. **Technical meeting on thalassaemia and haemoglobinopathies** - Regione Emilia-Romagna – Bologna – Dec 13, 2017.
2. **Meeting Club del Globulo Rosso & SITE** (Red Blood Cell Meeting Club – SITE). Professional training on Thalassaemia and Sickle Cell Disease management. Napoli, Aug 28-29, 2017.
3. **Technical meeting on thalassaemia and haemoglobinopathies** - Regione Emilia-Romagna – Bologna – 29 Jun 2017.
4. **EuroBloodNet pre-Kick-off Meeting**. Faculté de Médecine, Paris 10^{ème}. Jan 27, 2017. European Reference Network-EuroBloodNet.
5. **Theranostics in β -Thalassemia** - Dep. Of Life Sciences and Biotechnologies-University of Ferrara (Italy); Oct 20, 2016.
6. **IX National Congress S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies)**, Educational event targeted at professionals (physicians, biologists, nurses) involved in the global clinical management of patients with haemoglobinopathies. Catania (I) Oct 6-8, 2016.
7. **Celgene BELIEVE European Investigator's Meeting** – Protocol ACE536-B-THAL001 – Nice, Sep 15-18, 2016.
8. **"Il microambiente del Linfoma di Hodgkin, della Leucemia Linfoblastica Acuta e della Leucemia Mieloide Acuta"** (Microenvironment of Hodgkin Lymphoma, acute

lymphoblastic leukemia and acute myeloid leukemia), teaching for students in the fifth year of specialty in paediatrics. Feb 23, 2015 Paediatric Hematology and Oncology, Azienda Ospedaliero-Universitaria S. Anna di Ferrara.

9. **"Il Biologo: una professione preminente nella nutrizione e nella sicurezza alimentare"** (*The Biologist: a prominent profession in nutrition and food safety*) – Jun 27-28, 2015 - Auditorium of Italian Stand-EXPO Milan, Italy.
10. **"Presentation of the Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents"** – Ferrara, Sep 22-23, 2014.
11. **"Clinical Complication in Sickle Cell Disease and β -Thalassaemia & β -Thalassaemia and the THALAMOSS GA Meeting"**, Nicosia, Cyprus. Jun 25-27, 2014.
12. **"I livelli di concentrazione del ferro epatico. Metodi a confronto. (Liver Iron concentration. A comparison of methods)"** – Seminar – Apr 11, 2014 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy).
13. **"Riattivazione della sintesi di HbF dopo trapianto di midollo. Trapianto di midollo nella drepanocitosi e nella talassemia"** (Reactivation of HbF synthesis after bone marrow transplantation. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia) - Seminar - Jan 14, 2014 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy).
14. **"13th International Conference on Thalassemia & Hemoglobinopathies"** Thalassemia International Federation World Congress – Abu Dhabi, United Arab Emirates, Oct 20-23, 2013. **CME points: 24.**
15. **"Epatopatia cronica HCV nel paziente talassemico"** (Chronic HCV hepatopathy in thalassaemia patient) – Oct 12, 2013, Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy).
16. **"Seminario sull'Osteoporosi: Aspetti clinici e terapeutici nella talassemia"** (Seminar on Osteoporosis: Clinical and therapeutic aspects in thalassemia) - Sep 9, 2013 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy).
17. **"Talassemia Major e Osteoporosi"** (Thalassaemia Major and Osteoporosis) – Jun 11, 2013 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy).
18. **Hub&Spoke Net Meeting** – Regione Emilia-Romagna – Bologna, Apr 22, 2013.
19. **Hub&Spoke Net Meeting** – Regione Emilia-Romagna – Bologna, Apr 16, 2013.
20. **"Exjade. Ridefinire la Ferrochelazione"** (*Exjade. Re-defining the iron chelation treatment*) – Milan, Mar 22-23, 2013.
21. **"Ricerca e Innovazione nella cura della Talassemia"** (*Research and Innovation improving the clinical care of Thalassaemia*), Mar 15, 2013 – Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy).
22. **"Giornata Mondiale delle Malattie Rare- Formazione, Informazione ed Ascolto in Emilia-Romagna – IV Edition"** (*World rare diseases day – Training, Updating, and Listening in Emilia Romagna*) - Regione Emilia-Romagna – Bologna – Mar 2, 2013. **CME points: 5.2.**
23. **"ThalaMoss. THALAssaemia MOdular Stratification System for personalized therapy of β -thalassaemia"** Scientific Meeting, Ferrara, Jan 14-15, 2013 – Department of Life Sciences and biotechnology, University of Ferrara, Italy.
24. **"Il futuro delle Emoglobinopatie"** (*The future of the haemoglobinopathies*), VII National Conference, S.I.T.E. (Italian Society of Thalassaemia/Haemoglobinopathies), Sept 27-29, 2012 – Brindisi (Mesagne), Italy. **CME points: 7.5.**
25. **"Gruppo di Lavoro "Linfoma di Hodgkin"** (Hodgkin's Lymphoma Workshop). Mar 15, 2012, AIEOP (Paediatric Oncology/Haematology Italian Association) Clinic of Paediatrics – S. Anna Hospital, Ferrara (Italy).
26. **"EuroNet-PHL group meeting"**, Feb 10-11, 2012 Dublin, Ireland
27. **"Gruppo di Lavoro "Linfoma di Hodgkin"** (Hodgkin's Lymphoma Workshop). Sep 30, 2011 – AIEOP (Paediatric Oncology/Haematology Italian Association) Clinic of Paediatrics – S. Anna Hospital, Ferrara (Italy).
28. **"Il Laboratorio Africano Essenziale"** (The African essential clinical laboratory. Personal experience). Speaker at the meeting **"In Africa. Esperienze pediatriche Italiane"** (*Italian paediatric experiences in Africa*). Sep 10-11, 2010 – Palazzo Costabili, Ferrara, Italy.

29. **"First Training Course in Tanzania. Sixth African Training Course for a model of HIV infection treatment"**. Aug 3-12, 2005 – Arusha – Tanzania.
30. **"III International Meeting – DREAM – Un sogno per l'Africa: bambini senza AIDS"** (A dream for Africa: children without AIDS). May 27, 2005 Rome, Italy.
31. **"Le complicanze renali in talassemia"** (Renal failures in thalassaemia). Oct 16, 2004 III Congresso Nazionale SO.S.T.E., Oct 14-16, 2004 Cassana (FE), Italy.
32. **"Metabolismo osseo e terapia chelante"** (Bone metabolism and chelation therapy). Oct 15, 2004 III Congresso Nazionale SO.S.T.E., Oct 14-16, 2004 Cassana (FE), Italy.
33. **"Riunione Ricercatori Italiani coinvolti negli studi ICL670"** (Italian Researchers meeting on ICL670 study). May 12, 2004 Roma, Italy.
34. **"Investigators Meeting Studio CICAL670A0112"**. Oct 29-30, 2003 – NOVARTIS, Excelsior Hotel, Milano, Italy.
35. **"EDC Workshop"**. Apr 11, 2003 – NOVARTIS, headquarters of the pharmaceutical industry, Origgio, Italy.
36. **"Investigators' Meeting Protocol CICAL670A0107"**. Mar 10-11, 2003 – NOVARTIS, Hotel Mediterraneo, Cagliari, Italy.
37. **"Investigators' Meeting CICAL670A0107"**. Jan 13-15, 2003 – NOVARTIS, Hotel Montpamasse, Paris, France.
38. **"Novità in tema di Emoglobinopatie"** (Haemoglobinopathies update). Novembre 16, 2002, Nuove Cliniche, Azienda Ospedaliera-Universitaria Arcispedale S.Anna, Ferrara, Italy. CME points: 3.
39. **"Corso di aggiornamento relativo al software S.I.T." - Sistema Informatico Talassemia- per la gestione della cartella clinica computerizzata** (Course: S.I.T. for clinical data management at Thalassaemia Centre). Dec 4, 2002 - EMATIC S.r.l., Isola delle Femmine, Palermo, Italy.
40. **"Corso di aggiornamento della Società Italiana di Adolescentologia"** (Refresher course of Italian Society of Adolescence) Jun 2-3, 2000 – Società Italiana di Medicina dell'Adolescenza (S.I.M.A.) – Ferrara, Italy.
41. **"Adolescenza: verso un approccio multidisciplinare"** (Adolescence: towards a multi-disciplinar approach) May 8-9, 1998 - Associazione Catanzarese per gli Studi Auxologici (A.C.S.A.) – Endocrine Complications in Chronic Diseases Group (S.I.E.D.P.) - Hotel Guglielmo, Catanzaro, Italy. See Presentation: "Epatopatia nella Talassemia".
42. **"2nd International Workshop on Growth and Endocrine Complications & Reproduction in Thalassaemia"**- Apr 2-4, 1998 - Fondation Ares-Serono, Centro Congressi, Ferrara, Italy.
43. **"Trattamento dell'epatopatia cronica nel paziente talassemico"** (Treatment of chronic epatopathy in thalassaemia patient). Nov 27, 1997 - Roma, Italy.
44. **"Il comportamento alimentare"** (Nutrition behaviour). Oct 23, 1997 – Centro Congressi of Ferrara: Divisione Pediatrica – Prima Divisione Medica - Servizio Dietetico - Clinica Pediatrica - Clinica Psichiatrica, Azienda Ospedaliera-Universitaria, Ferrara, Italy.
45. **"Eziopatogenesi delle epatiti virali da HBV, HCV e nuovi virus epatotropi"** (Etiopathogenesis of HBV and HCV viral hepatitis and new hepatotropics viruses). Sep 24-26, 1997 – Meeting Centre of Grand Hotel Baglioni, Parma, Italy - Monotematica AISF 1997.
46. **"Osteoporosi. Aspetti diagnostico-terapeutici"** (Osteoporosis. Diagnostic and therapeutic aspects). May 30-31, 1991 - Nuovi Istituti Biologici, University of Ferrara, Italy.
47. **"Applicazione clinica degli anticorpi monoclonali"** (Clinical application of monoclonal antibodies). Feb 2, 1991 – Nuovi Istituti Biologici, University of Ferrara, Italy.
48. **"Markers del metabolismo osseo"** (Bone metabolism markers). Oct 24, 1990 - Medical System S.p.A., Nuovi Istituti Biologici, University of Ferrara, Italy.
49. **"Monitoraggio specifico della Ciclosporina con il metodo in fluorescenza polarizzata (FPIA): valutazioni e prospettive"** (Specific monitoring of Cyclosporin with polarized fluorescence (FPIA): evaluations and expectations). October 17, 1990 - Abbott S.p.A. Divisione Diagnostici, Palazzo dei Congressi, Bologna, Italy.
50. **"Generalità ed applicazioni cliniche dei marcatori tumorali"** (General principles and clinical applications of tumour markers). Sep 21, 1990 - Ares-Serono Diagnostici, Aula Magna University of Modena, Italy.

Publications

Papers Mention: 1043, by Academia platform for sharing academic research at Mar 20, 2023

Peer Reviewed

1. **"Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first line ibrutinib: a nationwide registry study from the Italian Medicines Agency"** GM Rigolin; PP Olimpieri; V Summa; S Celant; L Scarfò; L Tognolo; MP Ballardini; A Urso; M Sessa; S Gambarà; F Cura; **M Fortini**; P Ghia; A Cuneo; P Russo. *Leukemia* 2023, doi.org/10.21203/rs.3.rs-2585443/v1
2. **"Expression of γ -globin genes in β -thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalacilin)"** Zuccato, Cristina; Cosenza, Lucia Carmela; Zurlo, Matteo; Gasparello, Jessica; Papi, Chiara; D'Aversa, Elisabetta; Breveglieri, Giulia; Lampronti, Ilaria; Finotti, Alessia; Borgatti, Monica; Scapoli, Chiara; Stievano, Alice; **Fortini, Monica**, et al. *Ther Adv Hematol* 2022, Vol. 13: 1–24. DOI: 10.1177/20406207221100648
3. **"GH/IGF-1 axis in a large cohort of β -thalassemia major adult patients: a cross-sectional study"** I Gagliardi, R Mungari, MR Gamberini, **M Fortini**, et al. *J Endocrinol Invest.* 2022 Jul;45(7):1439-1445. Doi: 10.1007/s40618-022-01780-z. Epub 2022 Mar 19.
4. **"Expression of γ -globin genes in β -thalassemia patients treated with sirolimus: result from a pilot clinical trial (Sirthalacilin)"** C. Zuccato, LC. Cosenza, M. Zurlo, J. Gasparello, C. Papi, E. D'Aversa, G. Breveglieri, I. Lampronti, A. Finotti, M. Borgatti, C. Scapoli, A. Stievano, **M. Fortini** et al. *Ther Adv Hematol.* 2022, vol.13:1-24; doi.org/10.1177/20406207221100648.
5. **"Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry"** I. El-Battrawy, F. Longo, IJ. Nunez Gil, M. Abumayyaleh, B. Gianesin, V. Estrada, A. Aparisi, R. A. Espliguero, M. Balocco, S. Barella, A. Beccaria, F. Bonetti, M. Casale, E. DeMichele, A. Denotti, C. Fidone, **M. Fortini** et al. *J Cell Mol Med.* 2022 May;26(9):2520-2528. doi: 10.1111/jcmm.17026. Epub 2022 Mar 30.
6. **"Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience"** I. Gagliardi, M. Celico, MR. Gamberini, M. Pontrelli, **M. Fortini** et al. Original Research 2022 Mar 4, *Calcified Tissue International* https://doi: 10.1007/s00223-022-00963-3.; PMID: 35243531
7. **"Italian Patients With Hemoglobinopathies Exhibit A 5-Fold Increased in Age-Standardized Lethality Due To Sars-Cov-2 Infection"** F. Longo, B. Gianesin, V. Voi, I. Motta, VM. Pinto, A. Piolatto, A. Spasiano, GB. Ruffo, MR Gamberini, S. Barella, R. Mariani, C. Fidone, R. Rosso, M. Casale, D. Roberti, C. Dal Zotto, A. Vitucci, F. Bonetti, L. Pitrolo, M. Quaresima, M. Ribersani, A. Quota, F. Arcioni, S. Campisi, a. Massa, E. De Michele, R. Lisi, M. Miano, S. Bagnato, M. Gentile, V. Carrai, MC. Putti, M. Serra, C. Gaglioti, MM. De Amicis, G. Graziadei, A. De Giovanni, P. Ricchi, M. Balocco, S. Quintino, Z. Borsellino, **M. Fortini** et al. *Am J Hematol. Calcified Tissue International* https://doi.org/10.1007/s00223-022-00963-3 2022 Feb 1;97(2):E75-E78. doi: 10.1002/ajh.26429. Epub 2021 Dec 10.
8. **"Impact of the preparation method of red cell concentrates on transfusion indices in thalassemia patients: A randomized crossover clinical trial"** Maria Rita Gamberini, **Monica Fortini**, Alice Stievano, et al. *Transfusion.* 2021;61:1729–1739; https://doi.org/10.1111/trf.16432.
9. **"Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major"** F. Pellegrino, M.C. Zattelli, M. Bondanelli, **M. Fortini**, M.R. Gamberini, et al. July 2019 *Endocrine* 65(10) DOI: 10.1007/s12020-019-02003-x.
10. **"Spermatozoal DNA damage in patients with B thalassaemia syndromes"**. Perera D, Katz M, **Fortini M**, Gamberini MR. *De Sanctis V. Pediatr Endocrinol Rev* (2008) Volume: 6 Suppl 1, Pages: 185-9.
11. **"Chelation therapy and bone metabolism markers in thalassemia major"**. Pratelli L, Veri E, **Fortini M**, Marconi S, Zolezzi C, Fomasari PM, Gamberini MR, De Sanctis V. *J Pediatr Endocrinol Metab.* 2006 Nov;19(11):1335-42.
12. **"Paraplegia due to Spinal Cord Compression by Extramedullary Erythropoietic Tissue in a Thalassaemia Intermedia Patient with Gynecomastia Secondary to Cirrhosis:**

Successful Treatment with Hydroxyurea". Gamberini MR, **Fortini M**, De Sanctis V. *Pediatr Endocrinol Rev.* 2004 Dec;2 Suppl 2:316-8.

13. **"HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels"** Gamberini MR, Francesconi R, **Fortini M**, Cavazzini L, Lari F, Scapoli C, Ballardini G, De Sanctis V, Bianchi FB. *Pediatr Endocrinol Rev.* 2004 Dec;2 Suppl 2:259-66.
14. **"Diabetes Mellitus and Impaired Glucose Tolerance in Thalassaemia Major: Incidence, Prevalence, Risk Factor and Survival in Patients Followed at Ferrara Centre"**. Gamberini MR, **Fortini M**, De Sanctis V, Gilli G, Testa MR. *Ped Endocr Rev.* 2004 Dec;2 Suppl 2:285-91.
15. **"Healing of Leg Ulcers with Hydroxyurea in Thalassaemia Intermedia Patients with Associated Endocrine Complications"**. Gamberini MR, **Fortini M**, De Sanctis V. *Pediatr Endocrinol Rev.* 2004 Dec;2 Suppl 2:319-22.
16. **"Left ventricular remodelling and systolic and diastolic function in young adults with β -thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data"**. Bosi G, Crepaz R, Gamberini MR, **Fortini M**, Scarcia S, Bonsante E, Pitscheider W, Vaccari M. *Heart.* 2003 Jul;89(7):762-6.
17. **"Left Ventricular Remodeling, Systolic Function, and Diastolic Function in Young Adults with β -Thalassaemia Intermedia. A Doppler Echocardiography Study"**. Vaccari M, Crepaz R, **Fortini M**, Gamberini MR, Scarcia S, Pitscheider W, Bosi G. *Chest.* 2002 Feb;121(2):506-12.
18. **"Factors influencing final/near-final height in 12 boys with central precocious puberty treated with Gonadotrophin-releasing hormone agonists"**. Rizzo V., De Sanctis V., Corrias A., **Fortini M.**, Galluzzi F., Bertelloni S., Pozzan G., Cistemino M., Pasquino A.M., Italian Study Group of Physiopathology of Puberty *Journal of Paediatric Endocrinology & Metabolism*, 13, 781-786 (2000).
19. **"Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients"**. Gamberini MR, Fortini M, Gilli G, Testa MR, De Sanctis V. *J Pediatr Endocrinol Metab.* 1998;11 Suppl 3:867-9. Statistical elaboration of clinical data and linguistic revision.

Pre-Print Articles

1. **"Thalassaemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry"** I. El-Battrawy, F. Longo, IN Gil, M. Abumayyaleh, B. Giancesin, V. Estrada, A. Aparisi, R. Arroyo-Espliguero, M. Balocco, S. Barella, A. Beccaria, F. Bonetti, M. Casale, E. De Michele, AR. Denotti, C. Fidone, **M. Fortini** et al. Preprint article with *The Lancet*, March 10, 2021 (Trial Registration for sources of data extraction: NCT: 04334291, 04746066). DOI:10.2139/ssm.3801721.

Abstracts for Posters

1. **"Correzione genica della sequenza beta-globinica con mutazione beta³⁹ utilizzando il sistema di editing CRISPR-CAS9 in cellule eritroidi isolate da pazienti beta-talassemiaci"** (Gene correction of the beta-globin sequence with a beta³⁹ mutation, using the CRISPR-CAS9 editing system in erythroid cells isolated from beta-thalassaemic patients) A. Finotti, LC. Cosenza, J. Gasparello, M. Zurlo, C. Zuccato, C. Papi, MR. Gamberini, **M. Fortini**, R. Gambari. Abstract n. 037_XII Congresso Nazionale S.I.T.E. Sep 23-25, 2021, Rome (I).
2. **"Impact of the preparation method of red cell concentrates on transfusion indices in thalassaemic patients"** M. Gamberini, **M. Fortini**, A. Sievano et al. Abstract ISBTBarcelona-115_36th International Congress of the International Society of Blood Transfusion, ISBT-Barcelona, Dec 12-16, 2020.
3. **"Lumbar spine bone mineral density Z score discrepancy by DXA and QTC in thalassaemic major patients"** F. Pellegrino, L. Perrucci, M. Pontrelli, M.R. Gamberini, **M. Fortini**, I. Gagliardi, M.C. Zatelli, M.R. Ambrosio, M. Giganti. Poster # B-0046. 25th European Congress of Radiology (annual meeting of ESR), ECR 2019, The Bigger Picture, February 27-March 3 2019, Wien (A).
4. **"Incidence of vertebral fractures in patients with β -thalassaemia major in treatment with oral bisphosphonate"**. F. Pellegrino, M. Pontrelli, R. Mungari, **M. Fortini**, M.R. Gamberini, M.C. Zatelli, M.R. Ambrosio, M. Giganti. Poster # B-0045. 25th European Congress of Radiology (annual meeting of ESR), ECR 2019, The Bigger Picture, February

27-March 3 2019, Wien (A).

5. **"The Strong Link Between Pancreas and Heart in Thalassemia Major"**. A. Meloni, L. Pistoia, A. Spiga, **M. Fortini**, et al. HemaSphere 2018; 2(S1):694. Abstract subm. 28. Thalassemias, identifier EHA-1298 at 23rd Congress of the European Hematology Association, Stockholm, Sweden. June 14 - 17, 2018.
6. **"A MRI Prospective Survey on Heart and Liver Iron and Cardiac Function in Thalassemia Major Patients Treated with Deferasirox Versus Deferiprone and Desferrioxamine in Monotherapy"** A. Pepe, L. Pistoia, L. Cuccia, **M. Fortini**, V. Caruso et al. – ASH Annual Meeting & Exposition - Session 112. Thalassemia and Gene Regulation Poster III — San Diego, CA, December 3-6, 2016.
7. **"Confronto degli indici trasfusionali tra due metodi produttivi di Unità Trasfusionali in 132 pazienti talassemici del Centro di Ferrara"** (Comparison of transfusion indices between two RBC Units methods of production in 132 patients with Thalassaemia at Thalassaemia Centre of Ferrara, Italy). IX National Congress S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies), Catania (Italy), Oct 6-8, 2016.
8. **"Neoplasie maligne e benigne diagnosticate nella popolazione talassemica del centro di Ferrara"** (Malignant and benign tumours diagnosed among the thalassaemia patients of Ferrara) MR. Gamberini, **M. Fortini**, L. Manfredini, M. Sitta, M. De Lucia. VIII National Congress S.I.T.E. - Oct 9-11 2014, Genova (Italy).
9. **"Siderosi cardiaca ed epatica nei pazienti talassemici trasfusione-dipendenti e non: stato attuale presso il centro di Ferrara"** (Cardiac and hepatic siderosis in transfusion and non-transfusion-dependent thalassaemia patients: the current state at Thalassaemia Centre of Ferrara) MR. Gamberini, **M. Fortini**, L. Manfredini, M. Sitta, E. Chiodi, N. Romano. DOI: 10.13140/RG.2.1.1755.6247. VIII National Congress S.I.T.E. - Oct 9-11 2014, Genova (Italy).
10. **"Suscettibilità all'infezione da Parvovirus B19 in pazienti politrasfusi con talassemia"** (Susceptibility to Parvovirus B19 infection in multitransfused thalassaemia patient) MR. Gamberini, **M. Fortini**, L. Manfredini, M. Sitta, MP. Bianchi, M. Benni. VIII National Congress S.I.T.E. - Oct 9-11 2014, Genova (Italy).
11. **"Scompenso cardiaco da grave siderosi: completo ripristino della funzionalità d'organo in terapia con deferasirox"** (Cardiac impairment in patient with myocardial siderosis: complete improvement in cardiac function with deferasirox treatment) MR. Gamberini, **M. Fortini**, L. Manfredini, M. Sitta, E. Chiodi, M. De Lucia. VIII National Congress S.I.T.E. Oct 9-11 2014, Genova (Italy).
12. **"Terapia combinata deferasirox+desferioxamina in un caso di grave siderosi cardiaca ed epatica con disfunzione cardiaca: normalizzazione dei depositi e della funzione cardiaca"** (Deferasirox-Deferoxamine combination therapy in a serious cardiac and hepatic siderosis case with cardiac dysfunction: normalisation of cardiac iron load and cardiac function) MR. Gamberini, **M. Fortini**, L. Manfredini, M. Sitta, E. Chiodi, N. Roman. VIII National Congress S.I.T.E. Oct 9-11 2014, Genova (Italy).
13. **"25(OH)vitD levels and HCV infection, iron overload, cardiac and endocrine complications in patients with Thalassaemia Major"** M. Gamberini, **M. Fortini**, S. Bertelli, S. Pizzicotti. 13th International Conference on Thalassemia & Hemoglobinopathies. Oct 20-23, 2013 – Abu Dhabi (UAE).
14. **"Insufficiency fractures and asymptomatic vertebral fractures in adult patients with Beta-Thalassaemia Major"** MR. Gamberini, **M. Fortini**, N. Murri Dello Diago, M. Totaro, C. Zagà. 13th International Conference on Thalassemia & Hemoglobinopathies. Oct 20-23, 2013 – Abu Dhabi (UAE).
15. **"Adverse effects during PEG-INF+RBV treatment of chronic hepatitis C in multitransfused β -thalassemia patients"** MR. Gamberini, **M. Fortini**, S. Bertelli, MR. Govoni, M. Sprocati. 13th International Conference on Thalassemia & Hemoglobinopathies –Poster – Oct 20-23, 2013 – Abu Dhabi (UAE).
16. **"Eventi avversi in corso di terapia con PEG-INF+RIBA per epatite cronica HCV in pazienti politrasfusi con β -talassemia"** (Adverse events in the course of peg-INF+RBV antiviral treatment in multitransfused β -thalassaemia patients with chronic hepatitis C) M. Gamberini, S. Bertelli, **M Fortini**, MR. Govoni, M. Sprocati. VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies), Sep 27-29, 2012 – Brindisi (Mesagne), Italy.
17. **"Livelli di 25(OH)vitD ed epatopatia cronica HCV correlata, sovraccarico marziale,**

- complicanze cardiache ed endocrine nei pazienti con Talassemia Major** (25(oh)vitD levels and chronic hepatitis C, iron overload, cardiac and endocrine complications in β -thalassaemia major patients) M. Gamberini, S. Bertelli, **M Fortini**, MR. Govoni, M. Sprocati, S. Pizzicotti. VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopaties), Sep 27-29. 2012 – Brindisi (Mesagne), Italy.
18. **"Correzione della carenza di Vitamina D con Colecalciferolo in 23 pazienti politrasfusi affetti da β -talassemia"** (Deficit of Vitamin C treated with Cholecalciferol in 23 multitransfused β -thalassaemia patients) M. Gamberini, S. Bertelli, **M Fortini**, MR. Govoni, M. Sprocati, S. Pizzicotti. VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopaties), Sep 27-29, 2012 – Brindisi (Mesagne), Italy.
 19. **"Seasonal pattern in the occurrence of Hodgkin Lymphoma registered in the AIEOP MH'96 and LH2004 studies"**. R.Bumelli¹, E. Fabbri¹, G.Guerrini¹, P. Gallo¹, S.Rinieri¹, **M.Fortini¹**, and R.Rondelli² on Behalf of the Italian Association of Pediatric Hematology and Oncology (AIEOP). (1 Pediatric Department, Ferrara University, Italy; 2 Hematology and Oncology Unit- Bologna University, Italy). 1st international symposium on childhood, adolescent, and young adult Hodgkin Lymphoma - Arlington, Va, (USA) - May 12–14, 2011 I-ISCAYAHL abstracts-poster.
 20. **"Thyroid nodules and thyroid cancer in transfusion-dependent β -talassaemia patients"**. 12th International Conference on Thalassaemia and the Haemoglobinopathies, Thalassaemia International Federation (TIF). May 11-14, 2011 – Antalya (Turkey). <https://doi.org/10.4081/thal.2011.s1>
 21. **"Effects of chelation therapy on bone metabolism in β -thalassaemia"**. VI Congresso Nazionale IORS (Italian Orthopaedic Research Society) – Istituti Ortopedici Rizzoli, Bologna, Italy. Apr. 22-23, 2004-10-17.
 22. **"HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels"**. Abstract - 11th International Conference on Oral Chelation in the treatment of thalassaemia and other diseases – Mar 22-25, 2001 – Catania - SO.S.T.E. Notiziario, vol.2, n°1, p.118 – Apr. 2001.
 23. **"Latex allergy in multitransfused thalassaemia patients"**. Blood, Journal of the American Society of Haematology, 96, 23b, abstract# 3755 (Nov. 2000).
 24. **"Effetto della filtrazione sulle popolazioni eritrocitarie di differente età"** (Effect of filtration on erythrocytes of different age). Abstract – Haematology Meeting, Rimini 2000.
 25. **"Alterazioni della colonna vertebrale nei pazienti talassemici in trattamento chelante"** Abstract-(Spine defects in thalassaemia patients under chelation therapy). V Paediatric Neuroradiology National Congress – Firenze May 11-13, 2000.
 26. **"Fertility in males with thalassaemia"**. Abstract#1503 – 7th International conference on thalassaemia and haemoglobinopathies. Bangkok-Thailand, May 31- June 4, 1999. Statistical elaboration of clinical data.
 27. **"Meccanica ventricolare sinistra in giovani adulti con talassemia major in terapia trasfusionale cronica. Valutazione echo-doppler e correlazione con dati ematologici"** (Left ventricular mechanism in young thalassaemia major adult under chronic transfusion treatment. Echo-Doppler evaluation and correlation with haematological data). Abstract - XXX Cardiology National Congress (ANMCO) – Firenze, May 30 – Jun 2, 1999.
 28. **"Left ventricular mechanics in young adults with transfusion-dependent β -Thalassaemia Major"**. Abstract - Società Latina di Cardiologia Pediatrica, VIII International Meeting, Roma May 23-26, 1999.
 29. **"Growth, endocrine complications and reproduction in Thalassaemia Major"**. Abstract (pag. 96) - 1st International workshop on thalassaemia – New Delhi, Oct 30- Nov 5, 1998
 30. **"Modification of serum ferritin levels after Deferiprone administration to patients affected by β -Thalassaemia Major"**. 8th International Conference Oral Chelation in the Treatment of Thalassaemia and Other Diseases, Sept 19-21, 1997, Corfù.
 31. **"Evaluation of CA 549 in malignant neoplasms of the human breast"**. October 13-17, 1991 – XIX meeting - Scuola di Medicina dell'Istituto di Ostetricia e Ginecologia, and the International Society of Oncodevelopmental Biology and Medicine (I.S.O.B.M.), Siena, Italy.
- Works
1. **"HIV/AIDS: epidemiologic and evolutionary aspects, HIV genome, genetic diversity,**

- life cycle, host cellular environment, , pathogenesis, disease treatment in poor and developed countries, chronic disease in industrialised countries, treatment monitoring, PPD**", Teaching Hospital assignment – AUSL of Ferrara . Advanced training for general practitioners, hospital physicians, biologists, nurses. Jun 7-12, 2017, Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy). CME: 16
2. **"Tropical Neglected Diseases"**. Teaching Hospital assignment – AUSL of Ferrara. Advanced training for general practitioners, hospital physicians, nurses. Nov 10-24, 2016, Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 3. **"The most common tropical diseases. The tropical environment; the life cycle of malaria pathogen; haemoglobinopathies and protection against malaria; treatments and preventions"** Teaching Hospital assignment – AUSL of Ferrara. Advanced training for general practitioners and hospital physicians. Nov 12, 2015 – Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 4. **"Ebola Virus Disease: History, transmission, laboratory and clinical assessment, treatment, prevention and safety procedures for the epidemic control"**. Teaching Hospital assignment – AUSL of Ferrara. Advanced training for general practitioners and hospital physicians. Jun 16, 2015, Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 5. **"Clinical trials: logistics, conduction and GCPs"**, Teaching Hospital assignment – AUSL of Ferrara: Training course for physicians, biologist, pharmacists, professional nurses, technicians. Disciplines: Infectious diseases, Haematology, Obstetrics, General Medicine, Internal Medicine, Transfusion Medicine, Pharmacy, Laboratory for chemical and Physical Analysis and Microbiology. CME points for participants: 50. Feb 19, 2015, Congress Centre – Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 6. **"The most common tropical diseases. The tropical environment; the life cycle of most common pathogens; haemoglobinopathies and protection against Malaria; treatments and preventions"** Teaching Hospital assignment – AUSL of Ferrara: Training course for physicians, biologist, pharmacists, professional nurses, technicians. Disciplines: Infectious diseases, Haematology, Obstetrics, General Medicine, Internal Medicine, Transfusion Medicine, Pharmacy, Laboratory for chemical and Physical Analysis and Microbiology. CME points for participants: 50. Feb 5, 2015, Congress Centre – Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 7. **"Ebola Virus Disease. History, transmission, treatment, prevention and safety protocols for the epidemic control"**, Teaching Hospital assignment – AUSL of Ferrara: Training course for physicians, biologist, pharmacists, professional nurses, technicians. Disciplines: Infectious diseases, Haematology, Obstetrics, General Medicine, Internal Medicine, Transfusion Medicine, Pharmacy, Laboratory for chemical and Physical Analysis and Microbiology. CME points for participants: 50. Jan 23, 2015, Congress Centre – Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 8. **"Ebola Virus Disease. History, transmission, treatment, prevention and safety protocols for the epidemic control"**, Teaching Hospital assignment – AUSL of Ferrara: Training course for physicians, biologist, pharmacists, professional nurses, technicians. Disciplines: Infectious diseases, Haematology, Obstetrics, General Medicine, Internal Medicine, Transfusion Medicine, Pharmacy, Laboratory for chemical and Physical Analysis and Microbiology. CME points for participants: 50. Jan 23, 2015, Congress Centre – Azienda Universitario-Ospedaliera S.Anna – Ferrara (Italy).
 9. **"Clinical complications in Sickle Cell Disease and β -Thalassaemia"** – International Conference – 25-27 June 2014 – Nicosia, Cyprus. Presentation: **"Italy - THALAMOSS Data-Bank and patients for proteomics"** (Ref. THALAMOSS THEME [HEALTH.2012.1.2-1] [Development of technologies with a view to patient group stratification for personalised medicine applications] -project no. 306201).
 10. **"Late Diagnosis of osteoid osteoma in adolescence: a case report"**. Linguistic revision. D. Lacorte, V. Bonifacci, S. Bertelli, P.Gallo, M.Sprocati - Acta Medica Mediterranea, 2012, 28:29.
 11. **"Il laboratorio Africano Essenziale"**. M. Fortini. Medico e Bambino (Italian professional review for paediatricians and physicians). Vol 30, number 7; pg.439-440. September 30, 2011.
 12. **"Il microambiente del Linfoma di Hodgkin, della Leucemia Linfoblastica Acuta, della Leucemia Mieloide Acuta"** (Microenvironment Biology of Hodgkin's Lymphoma, Acute Lymphoblastic Leukaemia and Acute Myeloid Leukaemia) – June 9, 2011, Lesson – V year

specialisation in Paediatrics - Paediatric Section, S.Anna Hospital, Ferrara (Italy).

13. "**Osteology; Arthrology; Myology**". Anatomy I and II. Cycle of lessons at Institut Universitaire des Sciences de la Santé – Université de Ngozi – B.P. 137 Ngozi, Burundi. November 2007 – April 2010.
14. "**Les tissus en général; Les tissus épithéliaux de revêtement et glandulaires ; Les tissus conjonctifs; le tissu vasculaire; le tissu nerveux**". Hystology. Cycle of lessons at Institut Universitaire des Sciences de la Santé – Université de Ngozi – B.P. 137 Ngozi, Burundi. November 20-28, 2007/June 2008.
15. "**Haemocomponents transfusion management and reaction surveillance. Basic concepts in transfusion treatment**" Medical Seminar, C.M.E., May 30, 2007, St. Orsola Catholic Hospital, Matiri Mission, Tharaka District, Kenya.
16. "**Hygiene course**" Medical Seminar, C.M.E., May 16, 2007, St. Orsola Catholic Hospital, Matiri Mission, Tharaka District, Kenya.
17. "**Transfusion management course**" Medical Seminar, C.M.E., May 16, 2007, St. Orsola Catholic Hospital, Matiri Mission, Tharaka District, Kenya.
18. "**Growth and Chelation**". Publication - 11th International Conference on Oral Chelation in the treatment of thalassaemia and other diseases – Mar 22-25, 2001 – Catania - SO.S.T.E. Notiziario, vol.2, n°1, p.41 – Apr. 2001.
19. "**Compliance alla terapia ferrochelante con Deferroxamina**" (**Compliance to the iron chelation therapy with Desferroxamine**). Book. Translation from English version, intended for Italian care providers. Editor: Thalassaemia International Federation (TIF), Jul. 2000.
20. "**Clinica della β -Talassemia Major**" (**Clinical aspects of β -Talassemia Major**). Collaboration in Book: "**Clinica e Terapia della Talassemia**", collana "**Le emoglobinopatie oggi: dalla terapia alla prevenzione**" A. Maggio, Società Editrice Europea, Firenze, 2000.
21. " **β -Talassemia**"; "**Sickle Cell Disease**". Collaboration in Book: "**Problemi Ambulatoriali di Medicina dell'Adolescenza**", Pacini editor, p.254-258.
22. "**La Citometria a Flusso: Principi e Applicazioni Cliniche**" (Flow cytometry: principles and applications). Arcispedale S.Anna di Ferrara, Vol. XL, n°1, Jan-Mar, 1990.

I hereby agree for processing the following personal information, in accordance with the regulation for the protection of personal data in relation to the Article 13 of Regulation (EU) No 679/2016

APRIL 26, 2023

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that every entry should be supported by a valid receipt or invoice. This ensures transparency and allows for easy verification of the data.

In the second section, the author outlines the various methods used to collect and analyze the data. This includes both primary and secondary data collection techniques. The analysis focuses on identifying trends and patterns over time, which is crucial for making informed decisions.

The third part of the document provides a detailed breakdown of the results. It shows that there has been a significant increase in sales volume, particularly in the online channel. This is attributed to the implementation of the new marketing strategy and the improved user experience on the website.

Finally, the document concludes with a set of recommendations for future actions. It suggests continuing to invest in digital marketing and exploring new product lines. The author also notes that regular monitoring and reporting will be essential to track the progress of these initiatives.

Prepared by: [Name]

Date: [Date]